Wednesday, February 3, 2010

Dishman Pharma Q3 cons PAT down at Rs 33.1 cr

Dishman Pharma has declared its third quarter results. The company's Q3 consolidated net profit was down at Rs 33.1 crore versus Rs 39.6 crore.

Its consolidated net sales were up at Rs 222 crore versus Rs 282 crore.

The company's trailing 12-month (TTM) EPS was at Rs 9.95 per share. (Sep, 2009)

The stock's price-to-earnings (P/E) ratio stands at 22.73.
Source: CNBC-TV18
Courtesy moneycontrol.com








Also check

No comments:

Post a Comment